Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

We are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.

DC Investment Partners

HBM Healthcare Investments AG

Adage Capital Management

RA Capital Management

Longwood Fund

MPM Capital

Soleus Capital

Sphera Global Healthcare Fund

Taiho Ventures

UPMC Enterprises

Werewolf Therapeutics

We are excited to share preliminary monotherapy data from our WTX-124 Phase 1/1b clinical trial at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. https://bit.ly/45SOV8Y #ImmunoOncology #Cytokines #SITC2023 #HOWL

Excited to be at SITC in San Diego to present 6 posters sharing Wereowlf’s exciting advancement and data!

We’re #hiring a new Accountant in Watertown, Massachusetts. Apply today or share this post with your network.

Werewolf will be @ SITC and would welcome discussions with investors and partners. Reach out to me! See you in San Diego.

We are looking forward to the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Be sure to visit our six poster presentations, including interim first-in-human clinical data from our WTX-124 Phase 1/1b study. Learn More: https://lnkd.in/gjjR58w3
#ImmunoOncology #Cytokines #SITC2023 $HOWL

On Sunday 9/24 we are honored to recognize #WorldCancerResearchDay and raise awareness for #cancerresearch. At Werewolf we remain committed to transforming cancer treatment through innovation. Learn more here https://werewolftx.com/

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				16.40M -	19.94M 21.60%
cost of revenue					1.76M -
gross profit				16.40M -	18.18M 10.84%
selling and marketing expenses					-1.76M -
general and administrative expenses	3.60M -	5.76M 60.26%	14.82M 157.12%	18.70M 26.17%	18.67M 0.14%
selling general and administrative expenses	3.60M -	5.76M 60.26%	14.82M 157.12%	18.70M 26.17%	16.91M 9.57%
research and development expenses	6.34M -	16.64M 162.48%	35.27M 111.94%	53.76M 52.43%	41.78M 22.29%
other expenses	430K -	7.26M 1,589.07%	104K 98.57%	2.25M 2,059.62%	-1.14M 150.85%
cost and expenses	9.94M -	22.40M 125.48%	50.09M 123.56%	72.46M 44.66%	60.45M 16.58%
operating expenses	9.94M -	22.40M 125.48%	50.09M 123.56%	72.46M 44.66%	58.68M 19.01%
interest expense				-1.10M -	3.14M 384.33%
ebitda	-9.54M -	-22.25M 133.25%	-50.09M 125.07%	-56.06M 11.92%	-38.74M 30.89%
operating income	-9.94M -	-22.40M 125.48%	-50.09M 123.56%	-56.06M 11.92%	-40.50M 27.75%
depreciation and amortization	395K -	150K 62.03%	216K 44%	1.10M 411.11%	1.76M 59.78%
total other income expenses net	-312K -	7.36M 2,460.26%	104K 98.59%	2.25M 2,059.62%	3.13M 39.58%
income before tax	-10.25M -	-15.04M 46.76%	-49.98M 232.33%	-53.81M 7.66%	-37.37M 30.56%
income tax expense	742K -	-101K 113.61%	-216K 113.86%	-2.25M 939.81%
net income	-10.99M -	-14.94M 35.93%	-49.77M 233.13%	-51.56M 3.61%	-37.37M 27.53%
weighted average shs out	8.97M -	8.97M 0%	18.45M 105.72%	28.86M 56.40%	35.65M 23.50%
weighted average shs out dil	8.97M -	8.97M 0%	18.45M 105.72%	28.86M 56.40%	35.65M 23.50%
eps	-1.23 -	-1.67 35.77%	-2.70 61.68%	-1.79 33.70%	-1.05 41.34%
epsdiluted	-1.23 -	-1.67 35.77%	-2.70 61.68%	-1.79 33.70%	-1.05 41.34%

COM:WEREWOLFTX

Werewolf Therapeutics, Inc.

Last Close

1.51

14/02 21:00

Market Cap

95.60M

Beta: -

Volume Today

193.29K

Avg: -

Preview